NCT03119467 : A Phase I/Ib, Study to Evaluate Safety and Efficacy of RP4010, in Patients With Relapsed or Refractory Lymphomas

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

OnePhase One

Blood<br/>CancersCancer LocationBlood
Cancers

Systemic therapy | Blood / Myeloma / LymphomaAcute Lymphoblastic Lymphoma,B-Cell Non Hodgkin Lymphoma,Diffuse Large Cell Lymphoma,Follicular Lymphoma,Hodgkin's Disease (Hodgkin's Lymphoma),Lymphoma,Mantle Cell Lymphoma,Skin Lymphoma,T-Cell Lymphoma

Trial Overview Read MoreRead more

This phase I trial is testing escalating doses of a new oral therapy (RP4010) in lymphoma patients who have gotten worse or not responded to prior treatment.
 

This trial is treating patients with Lymphoma.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase I/Ib, Study to Evaluate Safety and Efficacy of RP4010, in Patients With Relapsed or Refractory Lymphomas

Commercial Sponsor

Rhizen Pharmaceuticals SA

Summary

This trial is evaluating the safety, pharmacokinetics and efficacy of RP4014, to be administered at escalating doses starting at 25 mg. This trial has a single group assignment.

Recruiting Hospitals Read MoreRead more

Epworth Hospital
Richmond
Ms Felicity Osmond
felicity.osmond@epworth.org.au
03 9936 8055

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next